|国家科技期刊平台
首页|期刊导航|中国药理学通报|靶向血小板的抗肿瘤药物研究进展

靶向血小板的抗肿瘤药物研究进展OACSTPCD

Research progress of antineoplastic drugs targeting platelets

中文摘要英文摘要

血小板长期以来一直被认为是止血和血栓形成的关键参与者;然而,越来越多的证据表明,它们也与癌症有关.临床前和临床研究表明,血小板可以通过血小板和癌细胞之间的各种串扰来促进肿瘤发生和转移.血小板在肿瘤发生的各个阶段,包括肿瘤生长、肿瘤细胞外渗和转移中都发挥着积极的作用.此外,癌症患者的血小板增多与患者不良生存率相关.由于大量的微粒和外泌体,血小板还能够很好地协调局部和远处的肿瘤-宿主之间的相互作用.因此,以血小板为靶点的抗肿瘤药物具有很大的开发与应用前景.以下将对靶向血小板的抗肿瘤药物研究进展进行综述.

Platelets have long been recognized as key players in hemostasis and thrombosis;however,there is growing evidence that they are also involved in cancer.Preclinical and clinical studies have shown that platelets can promote tumorigenesis and metastasis through various crosstalks between platelets and canc-er cells.Platelets play an active role in all stages of tumorigene-sis,including tumor growth,tumor cell extravasation,and me-tastasis.In addition,thrombocytosis in cancer patients is associ-ated with poor patient survival.Platelets are also well-placed to coordinate local and distant tumor-host interactions due to the a-bundance of microparticles and exosomes.Therefore,antitumor drugs targeting platelets have great development and application prospects.The following will review the research progress of an-ti-tumor drugs targeting platelets.

周玥珂;钱程;唐彧;韦忠红;陆茵;王爱云

南京中医药大学药学院,江苏省中药药效与安全性评价重点实验室,江苏南京 210023南京中医药大学药学院,江苏省中药药效与安全性评价重点实验室,江苏南京 210023||南京中医药大学江苏省中医药防治肿瘤协同创新中心,江苏南京 210023

基础医学

血小板活化血小板受体肿瘤血小板肿瘤细胞相互作用抗肿瘤药肿瘤发生和转移

platelet activationplatelet receptortumorplate-let-tumor cell interactionantitumor drugstumorigenesis and metastasis

《中国药理学通报》 2024 (001)

丹参酚酸/丹参酮类对血小板介导肿瘤血行转移的整合效应研究

20-25 / 6

国家自然科学基金资助项目(No 81573859);全国中医药创新骨干人才培训项目(国中医药人教函[2019]128号文);江苏省研究生科研创新计划(SJCX22_0791)

10.12360/CPB202208113

评论